Konstantinos C Spingos
Overview
Explore the profile of Konstantinos C Spingos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
65
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vikelis M, Argyriou A, Antoniou A, Spingos K, Skliros A, Bilias K, et al.
Medicina (Kaunas)
. 2023 Apr;
59(4).
PMID: 37109692
: Migraine is considered the most clinically important primary headache due to its high prevalence and significant burden. Although globally categorized as one of the leading causes of disability, it...
2.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
Medicina (Kaunas)
. 2023 Jan;
59(1).
PMID: 36676655
The Greek Society of Migraine and Headache Patients conducted, in 2020, its second online survey, titled "Migraine in Greece-2020", after publication of the first similar online survey conducted in 2018....
3.
Dermitzakis E, Kouroudi A, Argyriou A, Spingos K, Bilias K, Vikelis M
BMC Neurol
. 2022 Nov;
22(1):440.
PMID: 36411425
The Greek Society of Migraine and Headache Patients (GSMHP), maintaining a strong commitment to research and information, conducted its second web-based online survey named "Migraine in Greece-2020", following its first...
4.
Vikelis M, Dermitzakis E, Vlachos G, Soldatos P, Spingos K, Litsardopoulos P, et al.
J Clin Med
. 2020 Dec;
10(1).
PMID: 33375459
Background: To investigate the efficacy and safety of supplementation with a fixed combination of magnesium, vitamin B2, feverfew, andrographis paniculata and coenzyme Q10 in episodic migraine (EM) prevention. Methods: A...
5.
Vikelis M, Argyriou A, Dermitzakis E, Spingos K, Makris N, Kararizou E
J Headache Pain
. 2018 Sep;
19(1):87.
PMID: 30225735
Background: Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term treatment is still limited. We herein...
6.
Vikelis M, Spingos K, Rapoport A
Neurol Sci
. 2018 Jun;
39(Suppl 1):47-58.
PMID: 29904827
Primary headache disorders, such as migraine and cluster headache, are common and often debilitating. When preventive therapy is needed, several oral medications are used. Patients tend to have poor adherence...
7.
Vikelis M, Dermitzakis E, Spingos K, Vasiliadis G, Vlachos G, Kararizou E
BMC Neurol
. 2017 May;
17(1):97.
PMID: 28521762
Background: Migraine is included in the top-ten disabling diseases and conditions among the Western populations. Non-invasive neurostimulation, including the Cefaly® device, for the treatment of various types of pain is...
8.
Vikelis M, Argyriou A, Dermitzakis E, Spingos K, Mitsikostas D
J Headache Pain
. 2016 Sep;
17(1):84.
PMID: 27640152
Background: Chronic migraine is a disabling condition, with limited treatment options. We conducted an open label, single arm, prospective clinical trial, to assess the efficacy and safety of onabotulinumtoxin-A in...
9.
Vikelis M, Spingos K, Rapoport A
Ther Adv Neurol Disord
. 2015 Jul;
8(4):160-5.
PMID: 26136843
An iontophoretic transdermal system (ITS) (skin patch) formulation of sumatriptan for the acute treatment of migraine attacks was approved by the US Food and Drug Administration in January 2013. This...